ReviewCurrent pharmaceutical design2015
Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma.Molecular cancer therapeutics · 2026Article
- Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.Frontiers in pharmacology · 2026Review
- Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- Drug Delivery Systems for Respiratory Diseases: Insights into the Therapeutic Innovations for Pulmonary Administration.Pharmaceutics · 2025Article
- Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances.International journal of nanomedicine · 2025Review
- Pulmonary drug delivery for acute respiratory distress syndrome.Pulmonary pharmacology & therapeutics · 2023Review
- Advances in Lung Cancer Treatment Using Nanomedicines.ACS omega · 2023Review
- Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.Journal of drug delivery science and technology · 2022Review
- Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.European journal of medicinal chemistry · 2022Article
- Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody.Drug delivery · 2021Article
- Development of novel nanofibers targeted to smoke-injured lungs.Biomaterials · 2021Article
- Nanotherapeutics in the treatment of acute respiratory distress syndrome.Life sciences · 2021Review
- Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).Materials science & engineering. C, Materials for biological applications · 2020Article
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
- Short-Term Pulmonary Toxicity Assessment of Pre- and Post-incinerated Organomodified Nanoclay in Mice.ACS nano · 2018Article
- New perspectives in nanotherapeutics for chronic respiratory diseases.Biophysical reviews · 2017Article
- Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles.Journal of cellular and molecular medicine · 2017Review
- Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles.Research in pharmaceutical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inhalation of aerosolized compounds is a popular, non-invasive route for the targeted delivery of therapeutic molecules to the lung. Various types of nanoparticles have been used as carriers to facilitate drug uptake and intracellular action in order to treat lung diseases and/or to facilitate lung repair and growth. These include polymeric nanoparticles, liposomes, and dendrimers, among many others. In addition, nanoparticles are sometimes used in combination with small molecules, cytokines, growth factors, and/or pluripotent stem cells. Here we review the rationale and state-of-the-art nanotechnology for pulmonary drug delivery, with particular attention to new technological developments and approaches as well as the challenges associated with them, the emerging advances, and opportunities for future development in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.